The pharmaceutical company, which rivals AstraZeneca, says it was encouraged by underlying revenue growth which was driven by emerging markets and consumer health growth.
The stock has marginally underperformed the rest of the FTSE 100 on concerns over US Healthcare reform, however rose swiftly by about 1.2 pct on the news.
It remains down since however since then.
The profits at the group beat market expectation at £7.36 bn whilst margins were affected as the Group prepares its business to absorb any future US Healthcare reform.
Overall, profits were £2.23 billion and 30.7p earnings per share - slightly under some expectations of £2.41 billion and 31.3p earnings per share which investment bank Nomura gave.
The earnings however did beat consensus.
Posts
No comments:
Post a Comment